BioMarin Pharmaceutical Inc. (BMRN) Financials

$68.25

south_east
-$0.48 (-0.7%)
Day's range
$67.76
Day's range
$70.26
$3B$3B$2.5B$2.5B$2B$2B$1.5B$1.5B$1B$1B$500M$500M$0$0-$500M-$500MEarning2018201820192019202020202021202120222022202320232024202460%60%50%50%40%40%30%30%20%20%10%10%0%0%-10%-10%Profit Margin
Profit Margin
Revenue
Earnings

BMRN Income statement / Annual

Last year (2024), BioMarin Pharmaceutical Inc.'s total revenue was $2.85 B, an increase of 17.97% from the previous year. In 2024, BioMarin Pharmaceutical Inc.'s net income was $426.86 M. See BioMarin Pharmaceutical Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $2.85 B $2.42 B $2.10 B $1.85 B $1.86 B $1.70 B $1.49 B $1.31 B $1.12 B $889.90 M
Cost of Revenue $580.24 M $577.07 M $483.67 M $470.52 M $524.27 M $359.47 M $315.26 M $241.79 M $209.62 M $152.01 M
Gross Profit $2.27 B $1.84 B $1.61 B $1.38 B $1.34 B $1.34 B $1.18 B $1.07 B $907.23 M $737.89 M
Gross Profit Ratio 0.8 0.76 0.77 0.75 0.72 0.79 0.79 0.82 0.81 0.83
Research and Development Expenses $747.18 M $746.77 M $649.61 M $628.79 M $628.12 M $715.01 M $696.33 M $610.75 M $661.91 M $634.81 M
General & Administrative Expenses $0.00 $448.90 M $403.71 M $354.30 M $334.30 M $0.00 $604.35 M $554.34 M $476.59 M $402.27 M
Selling & Marketing Expenses $0.00 $488.40 M $450.30 M $405.10 M $403.40 M $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $1.01 B $937.30 M $854.01 M $759.38 M $737.67 M $680.92 M $604.35 M $554.34 M $476.59 M $402.27 M
Other Expenses $33.26 M $0.00 $67.19 M $69.93 M $66.66 M $74.11 M $2.21 M $7.97 M $4.93 M -$9.30 M
Operating Expenses $1.79 B $1.75 B $1.57 B $1.46 B $1.43 B $1.47 B $1.35 B $1.21 B $1.11 B $1.02 B
Cost And Expenses $2.37 B $2.27 B $2.05 B $1.93 B $1.96 B $1.83 B $1.66 B $1.45 B $1.32 B $1.17 B
Interest Income $74.88 M $58.34 M $18.03 M $10.48 M $16.61 M $22.75 M $22.83 M $14.85 M $7.49 M $4.50 M
Interest Expense -$12.67 M $17.34 M $15.97 M $15.34 M $29.31 M $23.46 M $43.66 M $42.71 M $39.50 M $38.24 M
Depreciation & Amortization $0.00 $104.39 M $101.97 M $108.04 M $105.88 M $105.30 M $95.50 M $87.92 M $86.03 M -$17.69 M
EBITDA $484.21 M $310.28 M $267.52 M $48.03 M -$5.85 M $33.95 M -$3.54 M $94.76 M -$705.53 M -$110.70 M
EBITDA Ratio 0.17 0.13 0.08 0.03 -0 -0.01 -0.07 -0.05 -0.17 -0.32
Operating Income Ratio 0.17 0.08 0.03 -0.03 -0.05 -0.07 -0.08 -0.01 -0.72 -0.12
Total Other Income/Expenses Net $57.55 M -$5.88 M $14,000.00 -$15.34 M -$5.56 M $5.65 M -$19.18 M -$35.86 M -$27.62 M -$44.02 M
Income Before Tax $541.76 M $188.56 M $149.58 M -$75.35 M -$42.32 M -$94.81 M -$142.71 M -$35.88 M -$831.05 M -$154.72 M
Income Before Tax Ratio 0.19 0.08 0.07 -0.04 -0.02 -0.06 -0.1 -0.03 -0.74 -0.17
Income Tax Expense $114.90 M $20.92 M $8.02 M -$11.27 M -$901.42 M -$70.96 M -$65.49 M $81.17 M -$200.84 M $17.08 M
Net Income $426.86 M $167.65 M $141.56 M -$64.08 M $854.03 M -$23.85 M -$77.21 M -$117.04 M -$630.21 M -$171.80 M
Net Income Ratio 0.15 0.07 0.07 -0.03 0.46 -0.01 -0.05 -0.09 -0.56 -0.19
EPS 2.25 0.89 0.76 -0.35 4.75 -0.13 -0.44 -0.67 -3.8 -1.07
EPS Diluted 2.17 0.87 0.75 -0.35 4.53 -0.13 -0.44 -0.67 -3.79 -1.07
Weighted Average Shares Out $190.03 M $187.83 M $185.27 M $182.85 M $180.80 M $179.04 M $177.06 M $174.43 M $165.99 M $160.03 M
Weighted Average Shares Out Diluted $196.71 M $191.60 M $188.96 M $182.85 M $191.68 M $179.04 M $177.27 M $174.43 M $166.22 M $160.03 M
Link